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SLC2A9 or Glut9 is a voltage sensitive urate transporter, mainly expressed in the
kidneys, the liver, and the intestine. Human Glut9 loss-of-function mutations were
identified in familial hypouricemia, and several single nucleotide polymorphisms (SNPs)
were associated with lower serum urate, further indicating that Glut9 is a major
determinant of serum uric acid level. To get insights in Glut9 transport characteristics,
we systematically analyzed the function of known human Glut9 mutants using 14C-
urate uptake assay and two-electrode voltage clamp (TEVC) in the Xenopus laevis
oocyte expression system. Surface expression was assessed by immunostaining and
biotinylation. We found decreased urate transport by flux studies for most of the variants.
No variant was permissive for glucose transport. We could further differentiate two
behaviors among the mutants: those harboring poor overall and cell-surface expression
leading to low activity and those fully expressed at the cell surface, but presenting
decreased activity. We studied the latter by TEVC and observed, in depolarized
conditions, decreased inward currents measured in presence of 400 µM urate, partially
reversed in 1 mM urate. In addition, we showed that C210F displays lower transport
ability. By contrast, N333S showed decreased urate transport activity and urate affinity,
suggesting that it may belong to the urate binding pocket. Systematic analysis of Glut9
mutants confirms Glut9 as putative target for the treatment of hyperuricemia and brings
new insights in Glut9 structure – function.
Keywords: SLC2A9, transporters, structure-function relationships, uric acid, site directed mutagenesis
INTRODUCTION
Uric acid (UA) is a weak acid mostly found as urate in the serum at physiological pH. Serum uric
acid (SUA) concentration, at steady state, is the result of a balance between its production due to the
activity of the liver enzyme xanthine oxidase (Watts, 1966), and of its elimination through either
its degradation by the enzyme uricase or by its excretion through the kidneys and the intestine
(Sorensen, 1965). Due to successive mutations in the gene coding for uricase (Wu et al., 1992),
humans lost the ability to degrade UA and have higher SUA concentrations by about thirty times
compared to other species (Keilin, 1959). If this might have led to evolutionary advantages, it also
contributes to significant morbidity, including gout, tophi and kidney stones.
In human kidneys, most of urate transport takes place in the proximal tubule and results in net
urate reabsorption of 90–95% of the filtered load. This process is complex, with reabsorption and
secretion intervening simultaneously and with many transporters involved. SLC2A9 (also called
Glut9 or URATv1) proved to be central to urate reabsorption, as indicated by several lines of
evidence.
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First, human mutations of SLC2A9 lead to Renal
Hypouricemia type 2 (RHUC-2, OMIM #612067), a monogenic
disease characterized by very low SUA (decreased by 70
to 90%), high fractional excretion of urate and occasional
exercise-induced acute renal failure (Polasek et al., 2010).
Several mutations in the SLC2A9 gene were reported so far
(Table 1) and most of them were studied functionally (Matsuo
et al., 2008; Dinour et al., 2010, 2012; Stiburkova et al., 2012;
Jeannin et al., 2014). However, methods and results were
disparate and sometimes inconsistent, giving rise to difficulties
in the interpretation of the pathogenicity of some variants. In
particular, P412R, was shown to display reduced Glut9-mediated
urate transport by functional studies in the Xenopus laevis
oocytes expression system by Anzai et al. (2008), but not by
Matsuo et al. (2008).
Second, if Glut9 mutants associated with RHUC-2 are rare
and occur in less than 1% of the population, some frequent
single nucleotide polymorphisms of SLC2A9 (V253I, rs16890979;
R265H, rs3733591; and P350L, rs2280205) were associated with
slightly lower SUA reduction of 5 to 10% (McArdle et al., 2008;
Hurba et al., 2014).
Third, two animal models carrying defective Glut9 proteins
(Dalmatian dog and mouse) displayed increased fractional
excretion of urate. Indeed, genetic analysis of the hyperuricosuric
Dalmatian dog breed revealed the presence of the C188F
mutation (corresponding to residue C210 in humans) in the
canine SLC2A9 gene (Bannasch et al., 2008) and Glut9 knockout
mice display high fractional excretion of urate, leading to
hyperuricosuria, tubular obstruction and renal failure (Preitner
et al., 2009).
TABLE 1 | List of published Glut9 variants studied in this work.
Glut9
variants
IDs Homozygous/
heterozygous
Allele Total
allelefre
quency
Origin Biological
characteristics
Normal range :
SUA : 155–430
µmol/L
FE : 5–10%
Populations at risk
(Top 3 Frequency)
Reference
L75R rs863225072 Homozygous A/C 1.682∗10−5 Human SUA = 10 µmol/L
FE>150%
European (4.232∗10−5) Dinour et al., 2010
T125M rs181509591 Homozygous G/A 1.263∗10−4 Human SUA = 12 µmol/L
FE>150%
Latino (6.974∗10−4), Other
(1.54∗10−4), European
(7.9∗10−5)
Dinour et al., 2012
R171C rs776127501 Heterozygous
Homozygous
G/A 4.069∗10−5 Human SUA = 259 µmol/L
FE = 4.9%
SUA = 6 µmol/L
FE = 128%
South Asian (9.746∗10−5),
East Asian (5.795∗10−5),
European (5.393∗10−5)
Dinour et al., 2012
R198C rs121908322 Heterozygous G/A 3.262∗10−5 Human SUA = 125 µmol/L South Asian (1.3∗10−4),
Latino (2.98∗10−5),
European (2.71∗10−5)
Matsuo et al., 2008
G216R rs561633150 Homozygous C/T 5.607∗10−4 Human (Associated with
N333S)SUA = 40
µmol/L
FE = 93%
South Asian (4.971∗10−3),
Other (3.1∗10−4)
Stiburkova et al., 2012
N333S rs75348295 Heterozygous T/C 8.176∗10−6 Human (Associated with
G216R
heterozygous)SUA = 30
µmol/L
FE = 46%
European (1.811∗10−5) Stiburkova et al., 2012
R380W rs121908321 Heterozygous G/A 1.986∗10−4 Human SUA = 90 µmol/L
FE = 16%
South Asian (1.3∗10−3),
East Asian (3.712∗10−4),
Latino (8.718∗10−5)
Matsuo et al., 2008
P412R rs121908323 Heterozygous G/C 5.98∗10−6 Human SUA = 143 µmol/L East Asian
(8.295∗10−5)
Anzai et al., 2008;
Matsuo et al., 2008
C210F n.a Dog Bannasch et al., 2008
V253I rs16890979 C/T 0.245 Human SUA −26.17 ± 3.57
µmol/L
African (0.436), Latino
(0.3978), South Asian
(0.2428)
McArdle et al., 2008;
Dehghan et al., 2008
R265H rs3733591 C/T 0.239 Human SUA −5.95 ± 4.16
µmol/L
East Asian (0.668), South
Asian (0.3619), European
(0.2389)
McArdle et al., 2008;
Yang et al., 2010;
Hollis-Moffatt et al., 2011
P350L rs2280205 G/A 0.437 Human SUA −7.14 ± 29.74
µmol/L
Ashkenazi Jewish (0.563),
Finnish European (0.5403),
Other European (0.5182)
McArdle et al., 2008;
Stiburkova et al., 2012
Frontiers in Physiology | www.frontiersin.org 2 June 2018 | Volume 9 | Article 476
fphys-09-00476 June 18, 2018 Time: 13:54 # 3
Ruiz et al. Analysis of Human SLC2A9 Variants
Finally, Anzai et al. (2008), Caulfield et al. (2008), Vitart
et al. (2008), Bibert et al. (2009) showed that Glut9 transports
urate efficiently with a Km of ∼650 µM and could be
modulated by the presence of fructose (Long et al., 2015).
Glut9 bears all characteristics of the basolateral voltage-
sensitive renal urate transporter previously described by
Roch-Ramel and Guisan (1999; Li et al., 2007; Dehghan et al.,
2008; Yang et al., 2010; Sulem et al., 2011). In particular, Glut9-
mediated urate transport proved to be sodium- and chloride-
independent, voltage-sensitive, and electrogenic (Anzai et al.,
2008; Caulfield et al., 2008; Vitart et al., 2008; Bibert et al., 2009).
Of note, two isoforms of hGlut9 are known: a long isoform
(Glut9a, 12 exons, 540 amino acids) and a short isoform (Glut9b
or Glut91N, 13 exons, 512 amino acids), that differ only at their
N-terminal part and display slight functional differences (Anzai
et al., 2008; Caulfield et al., 2008; Bibert et al., 2009).
Secondary structure of the Glut family was previously
described in great details for Glut1 by site-directed mutagenesis.
It was demonstrated that the protein harbors 12 transmembrane
domains, intracytoplasmic NH3- and COOH-terminal parts
and a single N-glycosylation site in the first extracellular loop
(Mueckler et al., 1985). These findings were recently confirmed
and refined by the resolution of the crystals of the closest bacterial
homolog, the xylose-H+ transporter XylE and by the crystals
of human Glut1 and Glut5 (Sun et al., 2012; Deng et al., 2014;
Nomura et al., 2015). In absence of mammalian Glut9 crystal, we
recently built up a first homology model based on XylE’s crystal
coordinates (Clemencon et al., 2014) and others have recently
studied critical Glut9 residues based on an homology model
developed on Glut5 crystal structure (Long et al., 2017). While
these major structural achievements helped understanding Glut9
architecture, several questions remain open, including the precise
localization of the binding site for urate or the urate translocation
mechanisms. In this study, we took advantage of known human
and Dalmatian loss-of-function mutants to systematically explore
the expression and activity of Glut9 and get insights about its
structure.
EXPERIMENTAL PROCEDURES
Materials and Chemicals
Mouse GLUT9a and b and GLUT2 complementary DNAs
(cDNAs) were obtained as described previously (Bibert et al.,
2009). Human GLUT9a and b cDNAs were purchased from
Imagene and subcloned in pSDeasy or in triple-FLAG (3xF)-
containing pCMV expression vectors. Amino acid numbering
refers to human Glut9a throughout the manuscript.
[14C]-urate with an activity of 50–60 mCi/mmol and [14C] D-
glucose with an activity of 2–10 mCi/mmol were purchased from
American Radiolabeled Chemicals, Inc.
Site-Directed Mutagenesis
Mutants were generated using two-steps PCR, as described
(Bonny et al., 1999). Primers were obtained from Microsynth AG,
Balgach, Switzerland. Amplicons and pSDeasy plasmid vectors
containing hGLUT9 were digested with cassettes as described TA
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FIGURE 1 | Glut9-mediated [14C] urate uptake in Xenopus laevis oocytes. (A) [14C] urate uptake was measured after 45 min incubation time in X. laevis oocytes
injected with human or mouse Glut9a, Glut9b or with water (H2O). Total concentration of urate in the uptake solution is 400 µM. (B,C) Glut9 transports [14C] urate,
but not [14C] D-Glucose. (D) The introduction of a triple flagged tag (Glut9 3xF) did not affect urate transport by Glut9. Statistical analysis were performed using a
Kruskal–Wallis test followed by a correction with Dunnett’s test (p < 0.05). Each bar represents the mean and standard deviation of 3 independent batches of
oocytes, with 10 oocytes per batch and condition. N.i, not injected; NS, not significant.
in Table 2. All constructs have been verified by sequencing
(Synergene Biotech GmbH, Zurich, Switzerland).
In Vitro Transcription
All mutants and wild-type cDNAs were linearized by PvuI
(Promega), except for L75R where NheI (Invitrogen) was used.
In vitro transcription was performed with SP6 mMESSAGE
mMACHINE Kit (Ambion, Life Technology). The cRNAs were
purified using RNeasy Mini Kit (QIAGEN).
Expression Into X. laevis Oocytes
Stages V–VI oocytes were selected from X. laevis (African
Xenopus Facility C.C, Knysna, Republic of South Africa
and Xenopus Express, Le Bourg, France). Experiments
were performed with the authorization of the Veterinarian
Office of the Canton de Vaud. Oocytes were injected
with 10 ng of either wild-type or mutant cRNAs, or
equivalent volume of water and incubated 48 h in
Modified Barth’s Solution (MBS) before experiments were
performed.
Western Immunoblotting
Ten oocytes of each condition were prepared as described
(Geering et al., 1996). Two µg of proteins were supplemented
with 2X solubilization buffer (SB) (60 mM Tris pH6.8, 5%
SDS, 20% Glycerol and 0.2% Bromophenol blue) containing
1.5% of 2-mercaptoethanol and then heated 10 min at 56◦C.
Proteins were separated on a 10% SDS polyacrylamide gel and
transferred onto nitrocellulose membrane (GE Healthcare Life
Science). Membranes were incubated overnight with anti-mouse
FLAG monoclonal antibody (Sigma) (1:500), followed by 1 h
with anti-mouse IgG-HRP (GE Healthcare Life Science), revealed
by ECL (Pierce Biotechnology, Inc.) and exposed on Kodak
films.
Biotinylation
All biotinylation steps were performed at 4◦C and according to
Harris et al. (2007). Twenty oocytes per condition were placed
for 15 min in biotinylation buffer containing 1 mg/mL EZ-
link sulfo-NHS-SS-Biotin (Pierce Biotechnology, Inc.), 10 mM
Triethanolamine, 150 mM NaCl, 2 mM CaCl2pH9.5. Quench
buffer (192 mM Glycine, 25 mM Tris HCl pH7.5 in MBS) was
added to stop the reaction, before washing three times with
MBS. Oocytes were then lysed [1% Triton X-100, 100 mM NaCl,
5 mM EDTA, 50 mM Tris HCl pH 7.5, 0.5% Na deoxycholate
and protease inhibitors (cOmplete Protease Inhibitor Cocktail
Tablet, Roche) and centrifuged 10 min at 12’000 rpm]. The
intermediate phase was transferred into new tubes and was
exposed overnight to NeutrAvidin Agarose Resin beads (Pierce
Biotechnology, Inc.). Beads were washed three times with lysis
buffer and heated 10 min at 56◦C in SB. Western blot was
performed as described above. Four biotinylation assays were
performed on independent batches of oocytes. Results were
quantified using Image J.
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FIGURE 2 | Transport studies on human Glut9 loss-of-function mutations. (A) [14C] urate uptake assay was systematically performed on published Glut9
loss-of-function mutants and revealed decreased activity for all of them (i.e., L75R, T125R, R198C, C210F, G216R, N333S, and R380W) except for mutants R171C
and P412R that do not reach significance. (B) None of these mutants displayed D-glucose transport activity when tested for [14C] D-glucose uptake.
(C) Immunohistochemistry with an anti-Flag antibody on cryosections of oocytes injected with WT-Glut9 or mutant showed conserved expression at the cell surface
for R171C, R198C, C210F, N333S, R380W, P412R and a decreased cell surface expression for L75R, T125M, and G216R. Representative pictures of three
experiments from different oocyte batches are shown. (D) Cell surface assessment by biotinylation assay on oocytes injected either with Glut9 WT or the designated
Glut9 mutants. One representative experiment out of 4 is shown. (E) Densitometric analysis revealed no difference in the ratio between biotinylation and total lysates
for each Glut9 mutant when compared to WT Glut9. (F) Summary of cell surface expression (biotinylation) and transport activity (urate uptake) of all tested mutants
reported to Glut9 WT. R198C, C210F, N333S, R380W, and P412R (in black) are the Glut9 mutants displaying preserved cell surface expression but decreased
transport activity. L75R T125M, R171C, and G216R (in gray) are less expressed than WT and except for R171C, have less activity. Statistical analysis was performed
using a Kruskal–Wallis test followed by a correction with Dunnett’s test (p < 0.05). Each experiment was performed on 3 independent batches of oocytes with 10
oocytes per batch and condition for uptake assay and 20 oocytes per condition for the biotinylation assay.
Urate and Glucose Uptake in X. laevis
Oocytes
Oocytes were incubated 45 min in MBS containing either
100 µM [14C]-urate with 300 µM cold urate (Bibert et al.,
2009) for urate uptake or containing 1 mM [14C] D-glucose
for glucose transport studies. Oocytes were washed five times
in cold MBS and transferred individually into vials containing
100 µL 5%SDS. Two mL of scintillation liquid (PerkinElmer)
was added before counting in a Packard analyzer. Three
independent batches with 10 oocytes per condition were
pooled.
Two Electrodes Voltage Clamp in
X. laevis Oocytes
Measurements were performed using a TEV-200A electrode
clamp (Dagan) and measured with Digidata (Axon instruments).
Oocytes were clamped at 0 mV and the current was recorded
for 20 s in presence or absence of different concentrations of
urate in 100 mM NaCl, 2.5 mM KCl, 10 mM Na-HEPES, 1 mM
MgCl2, 0.8 mM CaCl2 kept at pH 7.4. For I/V measurements,
recordings were performed from −120 mV to +60 mV with
20 mV increment steps. Each experiment was performed on three
independent batches with atleast five oocytes per batch.
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FIGURE 3 | Transport studies on Glut9 SNPs associated with low SUA. [14C]urate (A) and [14C]glucose (B) uptake in oocytes injected with Glut9 SNPs.
(C) Immunohistochemistry with an anti-Flag antibody of cryosections of oocytes injected with WT-Glut9 and SNPs V253I, R265H, and P350L reveals a decreased
expression at the cell surface for V253I. Protein expression was also verified by biotinylation and densitometric analysis (D,E). (F) Comparison of expression level and
activity of WT-Glut9 or SNPs. Statistical analysis was performed using a Kruskal–Wallis test followed by a correction with Dunnett’s test (p < 0.05) with 3 batches of
oocytes with 10 oocytes per batch and per condition for the fluxes and 20 oocytes for biotinylation.
FIGURE 4 | Electrogenicity of human Glut9 upon urate exposure. Representative trace current of H2O-(A) or Glut9-(B) injected oocytes in presence of 400 µM
urate. The dashed line represents the current at baseline (0 mV).
Urate dose/response studies were performed by measuring
sequentially the current after the perfusion of increasing
concentrations of urate for 30 s (0.4, 1, 2, 3, and 5 mM).
The voltage was clamped at 0 mV and each experiment was
done on five oocytes per condition and per batch (three
batches).
Immunohistochemistry
Eight µm oocyte cryosections were washed in PBS, blocked
in Normal Goat Serum (NGS) blocking buffer (10%NGS,
PBS 1X, 0.5% Tween in water) and incubated in the primary
mouse anti-FLAG antibody (Sigma) (1:500). Endogenous
peroxidase was quenched using 0.3% H2O2 (Sigma-Aldrich)
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FIGURE 5 | Electrophysiological studies of WT-Glut9. I/V curves for
H2O-injected and WT-Glut9-injected oocytes exposed to 400 µM (A) or 1 mM
(B) of urate. Three batches of oocytes were used with 5 oocytes per batch.
Data are means ±SD. Asterisks denote p < 0.05 between Glut9- and
H2O-injected oocytes.
and secondary biotinylated anti-mouse antibody (1:200)
(Vector Laboratories) was added. The slides were washed
and treated for 30 min with the avidin-biotin complex
(ABC) horseradish peroxidase (HRP). VECTOR NovaRED
Peroxidase Substrate kit (Vector Laboratories) was used for
detection. Sections were visualized under EVOSfl microscope
(AxonLab).
Building of the Glut9 3D Homology Model
3D model of human Glut9 was built by homology with the
human Glut1 transporter (pdb: 4PYP), using MODELLER 9.1
(Webb and Sali, 2014). View of the model was prepared with
UCSF Chimera (Pettersen et al., 2004). Full fitness was −1756,66
kcal·mol−1 and1G =−7.1 kcal·mol−1.
Statistics
Statistics were performed using Graphpad Prism 6.01 (Graphpad
Software Inc.). Kruskal–Wallis test followed by a Dunnett’s
correction test was used to compare mutants to wild-type in the
14C uptake assay. Multiple T-tests followed by the Bonferroni
correction were used to compare protein expression with the
activity displayed by every mutant. Finally, a Dunnett’s multiple
comparison test was used to compare concentration-response of
urate in mutant and water injected oocytes vs. WT. Vmax and
Km of urate kinetic analysis were determined from a non-linear
regression. P was considered as significant if<0.05.
RESULTS
Transport Activity and Expression of
Human Glut9 Mutants
We have previously shown that mouse Glut9 (mGlut9) transports
urate and we have suggested that the simplest model of transport
FIGURE 6 | Electrophysiological studies of mutants Glut9. I/V curves for the following Glut9 mutants measured at 400 µM and 1 mM urate were built: R198C (A),
C210F (B), N333S (C), R380W (D), and P412R (E). For the ease of comparison, the I/V curves for Glut9-WT and for water-injected-oocytes are represented on
each panel. Three batches of oocytes were used with 5 oocytes per batch. Asterisks denote p < 0.05 by unpaired t-test between WT-injected and mutant-injected
oocytes.
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FIGURE 7 | Concentration-response analysis for P412R. [14C]urate uptake
was measured in H2O, WT, or P412R-injected oocytes at increasing
concentrations of urate: 0.02, 0.20, 0.40, and 1 mM. Ten oocytes per batch
on 3 batches of oocytes were used. A Dunnett’s multiple comparison test was
used to compare P412R to WT and water (∗p < 0.05).
fitting our observations was a uniporter (Bibert et al., 2009). Here,
we first assessed human and mouse Glut9 isoforms a and b, by
[14C] urate uptake into X. laevis oocytes and showed that they
display the same transport rate (Figure 1A).We further verified
that urate transport was specific for Glut9 by comparing urate and
glucose uptake using Glut2 as control (Figures 1B,C). Finally,
and for convenience, a triple FLAG-tag epitope was added to
the C-terminal part of Glut9, with no effect on urate uptake
(Figure 1D).
With these tools in hands, Glut9 human and dog loss-
of-function mutations published so far (see Table 1) were
systematically examined in order to determine the cause
of the decreased activity in vivo and gain insights in Glut9
structure/function. Most of the mutants (L75R, T125M,
R198C, C210F, G216R, N333S, and R380W) displayed
significant decreased [14C]-urate uptake, while R171C and
P412R had preserved [14C]-urate uptake (Figure 2A),
with non-significant lower uptake compared to wild-type
Glut9 and significantly higher uptake than water-injected
oocytes. None of the Glut9 mutations showed any [14C]-
glucose uptake (Figure 2B), indicating that the mutations
did not result in a loss of affinity for urate in favor of
glucose.
We studied the expression level of Glut9-mutants compared
to wild-type Glut9-injected oocytes. Cell surface analysis by
immunohistochemistry revealed a strong decrease of protein
expression for Glut9 carrying the mutations L75R, T125M, and
G216R, while other mutants were expressed at a comparable
level as compared to wild-type Glut9 (Figure 2C). These findings
were further analyzed and quantified by a surface biotinylation
assay (Figure 2D). Interestingly, T125M and G216R appeared
to be expressed only in the non-glycosylated form, while
R171C expression seemed stronger in the fully glycosylated
state. However, when we normalized the cell surface expression
(biotinylated fraction) to the overall cell expression (total lysate),
no difference was observed between wild-type Glut9 compared
to the mutants (Figure 2E), suggesting that the decreased surface
expression was not due to defective sorting of the protein,
but mainly to decreased expression. Figure 2F summarizes
the expression level (surface biotinylation) and the transport
activity (urate uptake) of each of the mutant studied and allows
separation in two main categories: a group of mutants which are
well expressed and are present at the cell surface (R171C, R198C,
C210F, N333S, R380W, and P412R) and a group of mutants less
well expressed and having low transport activity (L75R, T125M,
and G216R).
FIGURE 8 | Electrophysiological studies of Glut9 SNPs. I/V curves built upon exposure to 400 µM or 1 mM of urate for: Glut9 WT and water-injected oocytes (A) or
Glut9 SNPs injected-oocytes: V253I (B), R265H (C), and P350L (D). For the ease of comparison, the I/V curves for Glut9-WT and for water-injected-oocytes are
represented on each panel. Three different batches of oocytes were used with 5 oocytes per batch. ∗Represents p < 0.05 compared to WT-injected oocytes.
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FIGURE 9 | Urate kinetics of WT-Glut9. Glut9-injected oocytes were
sequentially exposed to increasing urate concentrations (0.01, 0.1, 0.4, 1, 3,
and 5 mM) and current was recorded by TEVC, clamped at 0 mV. Each
measurement was repeated on atleast 5 oocytes per batch on atleast 3
batches. Detail analysis of Vmax and Km are reported in Table 3.
Transport Activity and Expression of
Human Glut9 Single Nucleotide
Polymorphisms (SNPs)
Three human Glut9 SNPs (V253I, R265H, and P350L) were
associated with low SUA in a genetic association study (Table 1)
(McArdle et al., 2008). SNPs transport activity was tested in
the X. laevis oocyte expression system. [14C]-urate transport
was significantly lower for the variant V253I when compared
to the wild-type (Figure 3A). No transport of [14C]-glucose
was observed (Figure 3B). Cell surface expression assessed
by immunohistochemistry showed decreased expression for
variant V253I (Figure 3C). This decrease was confirmed by
the biotinylation assay in which the expression of V253I was
decreased both in total lysate and at the cell surface (Figure 3D).
The ratio between total protein expression and cell surface
expression was constant, suggesting that no main trafficking issue
was accounting for the decreased expression (Figure 3E). This
data indicates that the SNP V253I has low urate transport activity
due to lower expression (Figure 3F). The two other SNPs studied
here were not different from wild-type when expressed in the
oocyte expression system.
TABLE 3 | Urate kinetics measurements of Glut9 mutants.
Vmax (µA) (mean ± SD) Km (mM) (mean ± SD)
WT 0.347 ± 0.175 0.433 ± 0.197
R171C 0.345 ± 0.105 0.411 ± 0.119
R198C 0.181∗ ± 0.056 0.603 ± 0.313
C210F 0.158∗ ± 0.056 0.497 ± 0.299
N333S 0.260 ± 0.169 1.221∗ ± 0.799
R380W 0.076∗ ± 0.021 0.839 ± 0.731
P412R 0.313 ± 0.082 0.434 ± 0.960
Oocytes were exposed to increasing extracellular urate concentrations (0.01, 0.1,
0.4, 1, 3, and 5 mM) and currents were measured by TEVC. The voltage was
clamped at 0 mV. Vmax and Km were determined from a non-linear regression. Each
value represents the mean of atleast 5 oocytes per batch from atleast 3 batches.
SD, standard deviation. ∗p < 0.05 compared to WT by 1 way ANOVA.
Electrophysiological Studies of Glut9 WT
and Variants
We have previously described electrogenic urate transport in
X. laevis oocytes injected with mouse Glut9 cRNA (Bibert et al.,
2009). Whether human Glut9 displays the same characteristics
was assessed by two-electrode voltage clamp at 0 mV measured
for 30 s in presence or not of 400 µM urate. We observed
positive currents in the 100 nA range upon application of urate
(Figures 4A,B). We further applied a voltage-clamped protocol
with voltage increment of 20 mV from −120 mV to +60 mV in
presence of 400 µM or 1 mM urate and measured the currents.
I/V curves were established. The negative reverse potential is
compatible with the transport of anions. For WT Glut9, no
significant difference in I/V curves could be made between
the two extracellular urate concentrations tested (400 µM and
1 mM). H20-injected oocytes had small currents influenced by
the voltage and by extracellular urate concentration, probably
due to some endogenous transporters present in the oocyte
(Figures 5A,B).
The same protocol was used to study the mutants showing
an expression level comparable to WT Glut9, but having low
activity by [14C]-urate uptake (R198C, C210F, N333S, R380W,
and P412R). R198C, C210F, and R380W had currents lower than
WT-Glut9 in presence of 400 µM of urate, a difference that
disappeared at higher extracellular urate concentration (1 mM)
when the membrane was highly depolarized (above +20 mV)
(Figures 6A,B,D). N333S displayed also lower currents than
WT-Glut9, but the increase in current after exposure to 1 mM
urate does not allow full recovery (Figure 6C). Finally, P412R
had higher currents than WT-Glut9 in the depolarized state in
presence of 400 µM of extracellular urate, getting even higher at
1 mM urate (Figure 6E). This interesting increase of activity of
Glut9 carrying the mutation P412R prompted us to verify [14C]-
urate uptake at increasing concentrations of urate (Figure 7).
We found higher urate uptake in presence of higher extracellular
urate concentrations.
The same study was performed on Glut9 SNPs V253I,
R265H, and P350L. V253I showed a decrease of the currents
in presence of 400 µM of urate, further decreased at
1 mM urate (Figure 8B). R265H and P350L showed only
minimal changes in currents compared to WT-Glut9, whether
the concentration of urate perfused is 400 µM or 1 mM
(Figures 8A,C,D).
To further study the electrophysiological characteristics of
Glut9 and the impact of the mutations on its properties, we
looked at the current response to increasing concentrations
of urate (0.01, 0.1, 0.4, 1, 3, and 5 mM) at a fixed voltage
(0 mV) and fitted the values according to Michaelis–Menten
kinetics. Urate kinetics for Glut9-WT revealed a Vmax ≈ 347 nA
with a Km of ≈0.43 mM (Figure 9). The same protocol
was used for each expressed mutant and the results obtained
are summarized in Table 3. Most mutants showed decreased
Vmax compared to Glut9-WT, except R171C, N333S, and
P412R. All mutants but N333S had the same affinity for urate
as Glut9-WT, with the exception of N333S that displayed
higher Km than WT, indicative of lower affinity for substrate
(Table 3).
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FIGURE 10 | Predicted secondary structure of Glut9. Representation of human Glut9 mutations and SNPs associated with variations of serum uric acid.
Transmembrane domains are indicated by gray boxes. Extracellular side is upper and intracellular side is lower. The corresponding five main residues involved in
glucose binding in hGLUT1 have been highlighted in yellow as indication.
FIGURE 11 | 3D homology model for Glut9, based on human Glut1 crystal structure. (A) Lateral view of Glut9-WT. (B,C) Represent views from the cytoplasmic side
into the direction of the putative pore of the transporter. The different helices are illustrated and the residues involved in human familial hypouricemia are illustrated in
red, as WT amino acids on (B) and as mutated amino acids on (C).
DISCUSSION
This study identified two main behaviors for Glut9 mutants
and variants: either the mutants were poorly expressed in the
oocyte expression system, leading to decreased transport activity,
or the mutants had preserved protein expression, and the
activity was decreased through changes in the intrinsic transport
activity. Both resulted in lower urate transport ability and explain
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the loss-of-function phenotype encountered in hypouricemic
patients carrying these mutations, except for P412R and R171C
which display only a moderate decrease in [14C]-urate transport
ability.
In the oocyte expression system, decreased expression level
of mutants L75R, T125M, and G216R was probably not due to
disturbed trafficking of the protein to the cell membrane, but
instead was due to a general decreased expression. RNA decay or
early protein degradation after quality check could account for
it. These mechanisms were, however, not further studied here.
Of note, mutations leading to poor expression are mainly found
in the transmembrane domains and are predicted to disrupt the
overall structure of the protein (Figure 10).
The second category of mutants (R171C, R198C, C210F,
N333S, R380W, and P412R) provides valuable information on
the mechanisms of urate transport through Glut9. If they
were all well expressed at the cell surface, their activity was
decreased significantly when studied by urate fluxes and by
electrophysiology. Interestingly, in electrophysiological studies,
the measured current, especially at high voltage, could be rescued
when higher extracellular urate concentrations were applied.
Further insights are provided by the analysis of the position
of these mutants in the protein. They are all comprised in the
transmembrane domains previously identified by site-directed
mutagenesis as important for Glut1-mediated glucose transport
and probably forming the glucose binding pocket in Glut1
(Figure 10).
In order to better localize the precise position of the mutants,
we designed a homology 3D model of Glut9 based on the
human Glut1 crystal recently published (Deng et al., 2014)
(Figure 11). We chose Glut1 and not the more recently described
Glut5 structure for two main reasons. First, the two proteins
share strong identity and similarity. Second, several amino acids
mutated in the human gene coding for Glut9 (R171, R198, C210,
and R380) and leading to familial hypouricemia type 2 are also
mutated in the human Glut1 gene (R126, R153, V165, R333) and
cause Glut1 deficiency syndrome, also called De Vivo syndrome
(Pascual et al., 2004). We found that all the mutants of the second
category (well expressed, with decreased function) are present
along the putative pore of Glut9, facing the internal lumen.
Further projections show that mutated residues are predicted to
either protrude in the lumen of the pore or interact physically
with some of the neighboring loops, suggesting that they might
induce significant changes in the structure of the protein.
C210F deserves a special note. This loss-of-function mutant
described in the Dalmatian dog breed, but never functionally
studied, was shown to be well expressed, but had only marginal
residual activity. Kinetic analysis revealed reduced transport
capacity but similar affinity for urate as compared to Glut9-WT.
This residue stands in the 5th transmembrane domain, facing
the pore and facilitating urate transport. By converting a polar
residue into an hydrophobic one, C210F probably decreases the
activity without altering the overall shape and thus expression of
the protein (Braun and von Heijne, 1999).
P412R turned to be intriguing. Initially identified in a
patient with a mild phenotype and carrying P412R in the
heterozygous state (Anzai et al., 2008), its causative role in
hypouricemia was challenged by expression studies which were
highly contradictory, with decreased activity (Anzai et al.,
2008) or no effect (Matsuo et al., 2008) described thus far. In
accordance with Matsuo et al. (2008) we found no significant
alteration of urate uptake in oocytes injected with P412R in
presence of 400 µM of urate. By contrast, when challenged
with higher external urate concentration (up to 1 mM) we
observed an increased transport activity for both, uptake and
current (Figures 6E, 7), with no change in affinity, though.
This is reminiscent to what was found for some Glut1 residues
close to the equivalent position in transmembrane domain 10
and displaying increased activity for both, uptake and current
(Figures 6E, 7), with no change in affinity, though. This
is reminiscent to what was found for some Glut1 residues
close to the equivalent position in transmembrane domain 10
and displaying increased activity when mutated in cysteine
(I369, V370, I372, and A377) (Mueckler and Makepeace, 2002).
Thus, the role of P412R remains ambiguous and no definitive
conclusion can be drawn from our studies performed in the
X. laevis oocyte expression system.
A key finding of this work is the lower affinity for urate of
the mutant N333S. N333 occupies a critical position in the pore
and its change in a serine decreased significantly Glut9 a ffinity
for urate. This was illustrated by an increased Km corroborated
by the fact that even 1 mM urate was not able to restore full
activity. This indicates that N333 is either situated directly in
the urate binding pocket or that N333S influences directly urate
binding. Interestingly, the key role of N333 in the transmembrane
translocation of Glut9 substrates was recently illustrated in an
analogy model of Glut9 built on the newly-deciphered Glut5
crystal structure (Long et al., 2017).
The functional analysis performed here on Glut9 single
nucleotide polymorphisms that are associated with lower SUA
and that were previously identified in a cohort of Old Order
Amish (McArdle et al., 2008) showed that one SNP (V253I)
is less expressed at the cell membrane and has less transport
activity than WT-Glut9. This finding was further confirmed
by electrophysiological measurements showing that V253I is
particularly sensitive to high extracellular urate concentrations.
These results are in slight contradiction with Hurba et al.
(2014) who showed a trend toward lower Glut9 activity for this
variant, not reaching significance though (Hurba et al., 2014).
We provide here strong evidence that surface expression (by two
methods: biotinylation and immunofluorescence) and activity
(by urate uptake and by TEVC) are decreased for this SNP in
the heterologous expression system of the X. laevis oocyte. The
two other SNPs studied did not behave differently compared
to WT. Further studies in human will be necessary in order to
show the relevance of these SNPs on urate homeostasis in larger
populations (Mancikova et al., 2016).
CONCLUSION
Overall, our study reveals that some loss-of-function Glut9
mutants are in direct interaction with the binding pocket and
the pore of the Glut9 urate transporter. We also showed for
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the first time that the Dalmatian mutation C210F decreased
Glut9 transport activity. This provides an explanation for the
phenotype observed in this dog breed. Additionally, we showed
that N333 is involved in the affinity of Glut9 for urate when
mutated in serine, suggesting that N333 locates in the binding
pocket. Finally, we showed that a frequent SNP of Glut9, V253I,
displays low transport activity due to defective targeting. This is
suggestive of a protective effect against hyperuricemia and gout
in humans.
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